Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Langdon

Showing results (31-40 of 180) with videos related to

Pageof 18
Sort By:
Expert Review of Anticancer Therapy|December 15, 2016
Endocrine therapy in epithelial ovarian cancerSimon P Langdon, Charlie Gourley, Hani Gabra, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1993
Pediatric HIV: Australian perspectiveJ B Ziegler, P Palasanthiran, M Cruickshank, et al.
British Journal of Urology|June 1, 1987
Orbital metastasis from prostatic carcinomaP R Harnett, D Raghavan, P Langdon, et al.
British Journal of Urology|May 1, 1991
Malignant phaeochromocytoma of the bladder--active or inactiveM Frydenberg, R Ferguson, P Langdon, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 1, 1994
Stability and in vitro metabolism of the mitogenic neuropeptide antagonists [D-Arg1,D-Phe5, D-Trp7,9, Leu11]-substance P and [Arg6, D-Trp7,9, MePhe8]-substance P (6-11) characterized by high-performance liquid chromatographyJ Cummings, A MacLellan, S P Langdon, et al.
Biochemical Pharmacology|April 1, 1984
Studies of the mode of action of antitumour triazenes and triazines-V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolismD Ross, S P Langdon, A Gescher, et al.
International Journal of Cancer|September 17, 1996
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell linesP Mullen, A Ritchie, S P Langdon, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapiesPoornima Paramasivan, Ibrahim H Kankia, Simon P Langdon, et al.
British Journal of Cancer|May 29, 2014
Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancerA Koussounadis, S P Langdon, D J Harrison, et al.
Cancers|June 26, 2020
Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian CancerSimon P Langdon, C Simon Herrington, Robert L Hollis, et al.
Pageof 18

Showing results (31-40 of 180) with videos related to

Sort By:
Pageof 18
Expert Review of Anticancer Therapy|December 15, 2016
Endocrine therapy in epithelial ovarian cancerSimon P Langdon, Charlie Gourley, Hani Gabra, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1993
Pediatric HIV: Australian perspectiveJ B Ziegler, P Palasanthiran, M Cruickshank, et al.
British Journal of Urology|June 1, 1987
Orbital metastasis from prostatic carcinomaP R Harnett, D Raghavan, P Langdon, et al.
British Journal of Urology|May 1, 1991
Malignant phaeochromocytoma of the bladder--active or inactiveM Frydenberg, R Ferguson, P Langdon, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 1, 1994
Stability and in vitro metabolism of the mitogenic neuropeptide antagonists [D-Arg1,D-Phe5, D-Trp7,9, Leu11]-substance P and [Arg6, D-Trp7,9, MePhe8]-substance P (6-11) characterized by high-performance liquid chromatographyJ Cummings, A MacLellan, S P Langdon, et al.
Biochemical Pharmacology|April 1, 1984
Studies of the mode of action of antitumour triazenes and triazines-V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolismD Ross, S P Langdon, A Gescher, et al.
International Journal of Cancer|September 17, 1996
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell linesP Mullen, A Ritchie, S P Langdon, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapiesPoornima Paramasivan, Ibrahim H Kankia, Simon P Langdon, et al.
British Journal of Cancer|May 29, 2014
Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancerA Koussounadis, S P Langdon, D J Harrison, et al.
Cancers|June 26, 2020
Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian CancerSimon P Langdon, C Simon Herrington, Robert L Hollis, et al.
Pageof 18